GDRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GDRX is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to allocate. The stock is trading in the low $2s with no strong proprietary buy signal, analyst targets have been cut sharply, fundamentals are weakening, and hedge funds are aggressively selling. While the options market shows a bullish put-call setup, the overall setup is more of a speculative hold than a clear long-term buy.
The stock is in pre-market at 2.3693, sitting just above pivot support at 2.324 and below near-term resistance at 2.395. MACD histogram is slightly positive and expanding, which supports short-term upward momentum. RSI_6 at 62.45 is neutral-to-mildly bullish, but moving averages are only converging rather than showing a strong trend. Overall, the chart suggests a mild short-term recovery attempt, not a decisive long-term breakout. The nearby resistance zone at 2.395-2.439 is the immediate test.
["Options sentiment is bullish, with very low put activity and strong call positioning.", "MACD histogram is positive and expanding, suggesting near-term momentum improvement.", "Wells Fargo still keeps an Overweight rating and Citi keeps a Buy rating despite target cuts.", "Pharma Direct is viewed by analysts as a potential growth driver."]
["No recent news catalyst in the last week.", "Analyst price targets have been cut across the board, including Wells Fargo, Citi, Goldman Sachs, Mizuho, UBS, TD Cowen, Deutsche Bank, and JPMorgan.", "Wells Fargo explicitly cited structural headwinds in Prescription Tx and pressure on near-term growth and margins.", "Revenue fell 1.91% YoY in the latest quarter and net income dropped 19.51% YoY.", "Gross margin declined 6.04% YoY, showing profitability pressure.", "Hedge funds are selling aggressively, with selling up 1160% last quarter.", "No recent insider buying, and no recent congress trading data."]
In 2025 Q4, GoodRx posted revenue of $194.8M, down 1.91% year over year, and net income of $5.4M, down 19.51% YoY. EPS was flat at $0.02, while gross margin fell to 79.15% from a higher prior-year level, down 6.04%. This points to slowing growth and margin compression in the latest quarter, with the business currently under pressure.
Analyst sentiment has weakened materially. Wells Fargo and Citi still have positive ratings, but both cut price targets to $3.50. Goldman Sachs, UBS, Mizuho, Deutsche Bank, and JPMorgan either downgraded or moved to Neutral/Hold, with several targets reduced to the $2-$3 range. The Wall Street view is mixed but leaning cautious: the bullish case focuses on Pharma Direct growth, while the bearish case centers on structural headwinds, lower take rates, and pressured 2026 outlook.
